CN120607606A - 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 - Google Patents
渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节Info
- Publication number
- CN120607606A CN120607606A CN202411603566.3A CN202411603566A CN120607606A CN 120607606 A CN120607606 A CN 120607606A CN 202411603566 A CN202411603566 A CN 202411603566A CN 120607606 A CN120607606 A CN 120607606A
- Authority
- CN
- China
- Prior art keywords
- receptor
- rage
- gpcrs
- activation
- certain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903381A AU2017903381A0 (en) | 2017-08-22 | Screening Assays, Modulators and Modulation of Activation of Receptor For Advanced Glycation End-Products (RAGE) | |
| AU2017903381 | 2017-08-22 | ||
| AU2018902298A AU2018902298A0 (en) | 2018-06-26 | Screening Assays, Modulators and Modulation of Activation of Receptor for Advanced Glycation End-Products (RAGE) | |
| AU2018902298 | 2018-06-26 | ||
| PCT/AU2018/050883 WO2019036753A1 (en) | 2017-08-22 | 2018-08-21 | SCREENING TESTS, MODULATORS AND MODULATION OF RECEIVER ACTIVATION FOR ADVANCED GLYCATION TERMINAL PRODUCTS (RAGE) |
| CN201880068213.4A CN111247163B (zh) | 2017-08-22 | 2018-08-21 | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880068213.4A Division CN111247163B (zh) | 2017-08-22 | 2018-08-21 | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN120607606A true CN120607606A (zh) | 2025-09-09 |
Family
ID=65438276
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411603566.3A Pending CN120607606A (zh) | 2017-08-22 | 2018-08-21 | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 |
| CN201880068213.4A Active CN111247163B (zh) | 2017-08-22 | 2018-08-21 | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880068213.4A Active CN111247163B (zh) | 2017-08-22 | 2018-08-21 | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12060408B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3672982B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7865475B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN120607606A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018322482B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109871A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019036753A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109871A1 (en) * | 2017-08-22 | 2019-02-28 | Monash University | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage) |
| KR102203850B1 (ko) * | 2019-04-09 | 2021-01-18 | 사회복지법인 삼성생명공익재단 | 신경교종의 진단 또는 예후 예측용 조성물 및 이에 관한 정보를 제공하는 방법 |
| EP4168548A1 (en) | 2020-06-22 | 2023-04-26 | Regeneron Pharmaceuticals, Inc. | Treatment of obesity with g-protein coupled receptor 75 (gpr75) inhibitors |
| WO2022150709A1 (en) * | 2021-01-11 | 2022-07-14 | President And Fellows Of Harvard College | Compositions and methods for treating viral infection |
| CN113293212A (zh) * | 2021-06-17 | 2021-08-24 | 深圳华因康基因科技有限公司 | 一种检测神经母细胞瘤复发转移基因fzd2扩增的引物探针及其应用 |
| CN113789379B (zh) * | 2021-08-30 | 2022-08-23 | 远见生物科技(上海)有限公司 | 一种检测前列腺癌的诊断试剂盒及其检测方法与应用 |
| JP2023084477A (ja) * | 2021-12-07 | 2023-06-19 | 花王株式会社 | 硫黄化合物を原因とするにおいの抑制剤の評価及び/又は選択方法 |
| WO2023140700A1 (ko) | 2022-01-24 | 2023-07-27 | 서울대학교산학협력단 | 장 미각 수용체 tas1r3 발현 및 활성화 억제를 통한 서구식 식이 유발 염증성 장 질환의 예방 또는 치료 |
| WO2023164290A2 (en) * | 2022-02-28 | 2023-08-31 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating cancers and other proliferative disorders |
| KR20230147988A (ko) * | 2022-04-15 | 2023-10-24 | 아주대학교산학협력단 | Rage 길항제 및 age 소거제를 포함하는 당뇨성 뇌졸중 예방 또는 치료용 약학적 조성물 |
| WO2024044659A1 (en) * | 2022-08-24 | 2024-02-29 | Tectonic Therapeutic, Inc. | Constitutively active g protein-coupled receptor compositions and methods of use thereof |
| CN115798616B (zh) * | 2022-10-26 | 2026-06-19 | 大连大学 | 基于dna链置换的新型生物分子控制器的实现方法 |
| CN118777620A (zh) * | 2023-04-07 | 2024-10-15 | 浙江友宁生物医药科技有限公司 | Gpr139受体激活检测方法、生理功能评价方法及应用 |
| CN116410335B (zh) * | 2023-04-24 | 2024-08-13 | 徐州医科大学 | 一种多肽tat-mrgprx1c及其应用 |
| CN118755834B (zh) * | 2024-07-15 | 2025-11-18 | 河北医科大学第四医院(河北省肿瘤医院) | 胃癌复发预测模型 |
| CN119901926A (zh) * | 2025-03-31 | 2025-04-29 | 浙江省立同德医院(浙江省精神卫生研究院) | 一种基于rage过表达和spr技术的rage靶向药物筛选方法 |
| CN121695261B (zh) * | 2026-02-11 | 2026-04-17 | 湖南启元生物科技有限公司 | 一种蛋白组合物及其制备方法 |
| CN121774990A (zh) * | 2026-03-05 | 2026-04-03 | 浙江省中医院、浙江中医药大学附属第一医院(浙江省东方医院) | 七叶皂苷钠在制备防治糖尿病视网膜病变药物中的应用 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5004687A (en) | 1985-05-21 | 1991-04-02 | University Of Georgia Research Foundation, Inc. | Insect virus vector with broadened host range |
| US4868103A (en) | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| CA2045129A1 (en) | 1989-02-01 | 1990-08-02 | Alfred I. Geller | Herpes simplex virus type i expression vector |
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| EP0549723A1 (en) | 1990-09-21 | 1993-07-07 | Chiron Corporation | Packaging cells |
| ATE188740T1 (de) | 1991-02-19 | 2000-01-15 | Univ California | Viruspartikel mit veraendertem wirtspektrum |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US6013638A (en) | 1991-10-02 | 2000-01-11 | The United States Of America As Represented By The Department Of Health And Human Services | Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung |
| EP0552108B1 (en) | 1992-01-17 | 1999-11-10 | Lakowicz, Joseph R. | Energy transfer phase-modulation fluoro-immunoassay |
| AU3972893A (en) | 1992-04-03 | 1993-11-08 | Baylor College Of Medicine | Gene therapy using the intestine |
| US6130074A (en) | 1992-06-01 | 2000-10-10 | American Cyanamid Company Five Giralda Farms | Recombinant insect virus with reduced capacity for host-to-host transmission in the environment and methods to produce said virus |
| SE9201984D0 (sv) | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| JP3147514B2 (ja) | 1992-07-08 | 2001-03-19 | 住友電装株式会社 | 電線送給装置 |
| AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| AU680508B2 (en) | 1993-04-06 | 1997-07-31 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Gibbon ape leukemia virus-based retroviral vectors |
| US6133028A (en) | 1993-05-28 | 2000-10-17 | Transgene S.A. | Defective adenoviruses and corresponding complementation lines |
| US6120764A (en) | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
| US6140087A (en) | 1993-06-24 | 2000-10-31 | Advec, Inc. | Adenovirus vectors for gene therapy |
| AU7353494A (en) | 1993-11-12 | 1995-05-29 | Case Western Reserve University | Episomal expression vector for human gene therapy |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5833993A (en) | 1994-04-29 | 1998-11-10 | Pharmacia & Upjohn Company | Feline immunodeficiency virus vaccine |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5662897A (en) | 1994-07-27 | 1997-09-02 | U. Of Ga Research Foundation | Insect viruses, sequences, insecticidal compositions and methods of use |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えdnaウイルスおよびその製造方法 |
| GB9506782D0 (en) | 1995-04-01 | 1995-05-24 | British Biotech Pharm | Retroviral vectors |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| JPH11511326A (ja) | 1995-08-30 | 1999-10-05 | ジエンザイム コーポレイション | アデノウィルスおよびaavの精製 |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6020192A (en) | 1996-01-18 | 2000-02-01 | University Of Florida | Humanized green fluorescent protein genes and methods |
| US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
| CA2247091A1 (en) | 1996-03-05 | 1997-09-12 | The Regents Of The University Of California | Recombinant live feline immunodeficiency virus and proviral dna vaccines |
| US5952221A (en) | 1996-03-06 | 1999-09-14 | Avigen, Inc. | Adeno-associated virus vectors comprising a first and second nucleic acid sequence |
| US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6143565A (en) | 1997-08-22 | 2000-11-07 | The United States Of America As Represented By The Secretary Of Agriculture | Stable insect virus-cell expression system |
| US6893827B1 (en) | 2000-02-07 | 2005-05-17 | Applera Corporation | Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation |
| EP1345968A2 (en) | 2000-12-28 | 2003-09-24 | Altus Biologics Inc. | Crystals of whole antibodies and fragments thereof and methods for making and using them |
| JPWO2003008446A1 (ja) | 2001-07-19 | 2004-11-11 | 三菱ウェルファーマ株式会社 | 後期糖化産物受容体のシグナル伝達に関連するポリペプチド |
| CN1894581B (zh) | 2003-07-09 | 2012-02-01 | 生命技术公司 | 检测蛋白-蛋白相互作用的方法 |
| US7488583B2 (en) | 2003-09-25 | 2009-02-10 | Odyssey Thera, Inc. | Fragment complementation assays for G-protein-coupled receptors and their signaling pathways |
| ES2473587T3 (es) | 2004-08-03 | 2014-07-07 | Transtech Pharma, Inc. | Proteínas de fusión de RAGE y métodos de uso |
| EP1869464A4 (en) | 2005-03-17 | 2009-12-02 | Univ Columbia | RAGE-DIAPHANOUS INTERACTION AND CORRESPONDING COMPOSITIONS AND METHODS |
| JP5295785B2 (ja) | 2006-02-20 | 2013-09-18 | エファ・ユニバーシティ・インダストリー・コラボレイション・ファウンデイション | 細胞膜透過性ペプチド |
| MX2008011933A (es) | 2006-03-21 | 2008-12-18 | Wyeth Corp | Metodos y composiciones para antagonismo de rage. |
| WO2008055314A1 (en) | 2006-11-10 | 2008-05-15 | Dimerix Bioscience Pty Ltd | Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers |
| WO2008154638A2 (en) | 2007-06-12 | 2008-12-18 | Board Of Regents, The University Of Texas System | Antagonists of the receptor for advanced glycation end-products (rage) |
| US8101373B2 (en) | 2007-10-12 | 2012-01-24 | Discoverx Corporation | β-galactosidase donor fragments |
| WO2012109569A1 (en) | 2011-02-11 | 2012-08-16 | The Trustees Of Columbia University In The City Of New York | The receptor for advanced glycation endproducts (rage) is a receptor for lysophosphatidic acid (lpa) |
| WO2012159164A1 (en) | 2011-05-23 | 2012-11-29 | Phylogica Limited | Method of determining, identifying or isolating cell-penetrating peptides |
| EP2756005B1 (en) | 2011-09-14 | 2016-03-02 | Abeterno Technologies Limited | Intracellular cell selection |
| CA3109871A1 (en) * | 2017-08-22 | 2019-02-28 | Monash University | Screening assays, modulators and modulation of activation of receptor for advanced glycation end-products (rage) |
-
2018
- 2018-08-21 CA CA3109871A patent/CA3109871A1/en active Pending
- 2018-08-21 JP JP2020511214A patent/JP7865475B2/ja active Active
- 2018-08-21 US US16/641,174 patent/US12060408B2/en active Active
- 2018-08-21 CN CN202411603566.3A patent/CN120607606A/zh active Pending
- 2018-08-21 WO PCT/AU2018/050883 patent/WO2019036753A1/en not_active Ceased
- 2018-08-21 AU AU2018322482A patent/AU2018322482B2/en active Active
- 2018-08-21 EP EP18849151.8A patent/EP3672982B1/en active Active
- 2018-08-21 CN CN201880068213.4A patent/CN111247163B/zh active Active
-
2023
- 2023-07-26 JP JP2023121818A patent/JP7855180B2/ja active Active
-
2024
- 2024-08-13 US US18/802,964 patent/US20250019415A1/en active Pending
-
2025
- 2025-12-03 JP JP2025227130A patent/JP2026062654A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3672982A1 (en) | 2020-07-01 |
| JP7855180B2 (ja) | 2026-05-08 |
| JP2023156353A (ja) | 2023-10-24 |
| JP2020531514A (ja) | 2020-11-05 |
| EP3672982A4 (en) | 2021-06-09 |
| US20200207836A1 (en) | 2020-07-02 |
| WO2019036753A1 (en) | 2019-02-28 |
| EP3672982B1 (en) | 2026-07-08 |
| JP7865475B2 (ja) | 2026-05-26 |
| US20250019415A1 (en) | 2025-01-16 |
| US12060408B2 (en) | 2024-08-13 |
| JP2026062654A (ja) | 2026-04-10 |
| AU2018322482A1 (en) | 2020-04-02 |
| CA3109871A1 (en) | 2019-02-28 |
| CN111247163B (zh) | 2024-11-26 |
| AU2018322482B2 (en) | 2024-04-04 |
| CN111247163A (zh) | 2020-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111247163B (zh) | 渐进性糖化终极产物受体(rage)活化的筛选测定法、调节物和调节 | |
| Meyrath et al. | Proadrenomedullin N‑Terminal 20 Peptides (PAMPs) Are Agonists of the Chemokine Scavenger Receptor ACKR3/CXCR7 | |
| JP2018511329A (ja) | Gpcrアゴニストポリペプチドに関連する方法および組成物 | |
| CN101027560A (zh) | 用于治疗高血糖症和相关病症的人类g蛋白偶合受体及其调节物 | |
| WO2000040725A1 (fr) | Methode d'analyse | |
| Cook et al. | Cleavage of the angiotensin II type 1 receptor and nuclear accumulation of the cytoplasmic carboxy-terminal fragment | |
| Billard et al. | Discovery of new allosteric modulators of the urotensinergic system through substitution of the urotensin II-related peptide (URP) phenylalanine residue | |
| Deng et al. | Structure–activity relationship of GPR15L peptide analogues and investigation of their interaction with the GPR15 receptor | |
| KR20010081109A (ko) | 신규 g 단백질 공액형 리셉터단백질, 그 dna 및 그리간드 | |
| US8142762B2 (en) | Methods of using GPR101 receptors to identify modulators of hypothalamic proopiomelanocortin (POMC)-derived biologically active peptide secretion | |
| DK2895189T3 (en) | PEPTID ANTAGONISTS OF THE VASOPRESSIN-2 RECEPTOR | |
| Corbani et al. | Design, synthesis and pharmacological characterization of fluorescent peptides for imaging human V1b vasopressin or oxytocin receptors | |
| US20220169693A1 (en) | Screening Assays, Modulators and Modulation of Intracellular Signalling Mediated by Immunoglobulin Superfamily Cell Adhesion Molecules | |
| US7611832B2 (en) | Human G protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure | |
| WO2001040797A1 (fr) | Procede de criblage | |
| WO2001057524A1 (fr) | Procede de criblage | |
| Schulein et al. | Functional significance of the signal peptides of corticotropin-releasing factor receptors | |
| US20090317332A1 (en) | Human g protein-coupled receptor and modulators thereof for the treatment of obesity and conditions related thereto | |
| Delaitre et al. | Synthesis and Pharmacological Characterization of Fluorescent Ligands Targeting the Angiotensin II Receptors Derived from Agonists, β‑Arrestin-Biased Agonists, and Antagonists | |
| WO2005121356A1 (ja) | 新規スクリーニング方法 | |
| Zheng et al. | Arrestin-3 sca-olds multiple MAP3Ks driving stress-induced JNK3 activation and cell death | |
| Fakhfouri | Interventions pharmacologiques affectants spécifiquement la signalisation du récepteur D2 de la dopamine médiée par la beta arrestine 2 | |
| JP2001309792A (ja) | スクリーニング方法 | |
| Grämer | Development of a GRK2-inhibitory peptide | |
| JP4533655B2 (ja) | 新規スクリーニング方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |